Benzodiazepines (BDZs) bind to the gamma sub-unit of the GABA-A receptor. Their binding causes an allosteric (structural) modification of the receptor that results in an increase in GABA A receptor activity. BDZs do not substitute for GABA, which bind at the alpha sub-unit, but increase the frequency of channel opening events which leads to an increase in chloride ion conductance and inhibition of the action potential.1
Related content
Professor Dr. Per Borghammer unpacks the brain-first vs body-first model of Parkinson’s disease, exploring distinct pathways of progression from the gut or nose and their potential to drive personalized medicine and innovative treatments.
Discover how human models of migraine have identified key molecular triggers like CGRP and PACAP, revolutionizing treatment options and offering hope for patients unresponsive to current therapies.
In this video, Professor Christoph Correll, Chair of the Neurotorium Editorial Board, introduces Neurotorium.